{
    "title": "103_s1429",
    "content": "The Act titled \"Women and AIDS Research Initiative Amendments of 1993\" establishes a program for research on women and AIDS. The Secretary will establish a program for biomedical and behavioral research on HIV cases in women, including prevention research. Grants may be provided to entities for research. Research will focus on how HIV is transmitted to women. The Secretary will provide for research on the transmission of HIV to women, including the relationship with other sexually transmitted diseases and prevention measures. This includes research on preventing sexually transmitted diseases that may facilitate HIV transmission. Research on the transmission of HIV to women includes prevention of sexually transmitted diseases that may facilitate virus transmission, rapid and inexpensive diagnostic tests, single-dose therapy, prevention methods for women, and dissemination of prevention programs and materials. The curr_chunk discusses the development and dissemination of prevention programs to reduce substance abuse among women, research on symptoms resulting from HIV infection, including gynecological and hormonal changes, and the treatment of HIV cases through clinical research. The curr_chunk focuses on the treatment of HIV cases, including clinical research and behavioral research on prevention programs. It also mentions gynecological evaluations in clinical trials involving female subjects infected with HIV. The text chunk discusses the requirement for gynecological examinations for female subjects infected with HIV in clinical trials, including follow-up services and analysis of the results to understand the relationship between gynecological conditions and the virus. The Secretary will conduct clinical trials to determine the effectiveness of standard treatments for gynecological conditions that arise from HIV infection. The Secretary will conduct clinical trials to determine if approved HIV treatment protocols for men are effective for women with the virus. Support services like transportation and child care will be provided to women participating in these trials. The Secretary will provide women participating in clinical trials with transportation, child care, and support services, including medical and mental health services, drug abuse treatment, and services addressing domestic violence. These services are tailored to meet the specific needs of women in clinical trials, including training. The Secretary will provide women in clinical trials with support services, including medical and mental health services, drug abuse treatment, and services addressing domestic violence. Research will be conducted on barrier methods for preventing sexually transmitted diseases, including HIV, that women can use without their partner's knowledge. Research will be prioritized for barrier methods to prevent sexually transmitted diseases, including HIV, that women can use without their partner's knowledge. This includes research on early infectious stages and formulation of topical microbicides. The Secretary will conduct or support research on early infectious stages, formulation of new preparations, clinical testing for safety and efficacy, and acceptability of microbicides. Epidemiological research will be done to determine infection risk factors. The Secretary will conduct or support epidemiological research to determine risk factors for HIV infection in women, including contraceptive methods, tampon use, relationship with other STDs, and substance abuse. The Secretary is conducting a study on HIV infection in women, including risk factors like substance abuse and sexual activity. The study aims to monitor the progression of HIV in women compared to men, with a focus on the Women's Interagency HIV Study involving at least 5,000 participants. The Women's Interagency HIV Study includes at least 5,000 women with HIV infection, conducted at multiple sites over an 8-year period. The study focuses on the relationship between CD4 cells and other markers in women with HIV. The study addresses the relationship between the number of cells and markers in women with HIV infection and the development of serious illnesses. It includes gynecological conditions and other conditions specific to women not currently on the CDC's list. The term 'human immunodeficiency virus' refers to the agent for acquired immune deficiency syndrome. Prevention. The term 'human immunodeficiency virus' refers to the agent for acquired immune deficiency syndrome. Authorizations of Appropriations for clinical trials include $20,000,000 for fiscal year 1994 and necessary sums for fiscal years 1995 through 1996. For fiscal years 1995 through 1996, $10,000,000 is authorized for subsection (c)(2) and (c)(3) of the Prevention Act. For fiscal years 1994 through 1996, $15,000,000 is authorized for subsection (c)(4) and $30,000,000 for subsection (d)(1) of the Prevention Act. For fiscal years 1994 through 1996, $55,000,000 is authorized for various subsections of the Prevention Act, with specific amounts allocated for different purposes."
}